Market Report forecasts growth across 7 major markets, reaching $25.9 billion by 2033 with a 1.7% CAGR. Driven by new DMTs and high-efficacy treatments, the market faces brand erosion from biosimilars ...

"The on-schedule enrollment of the final patients in our phase 3 ENSURE trials of vidofludimus calcium marks another significant milestone for our late-stage MS program, bringing us meaningfully ...

A major scientific breakthrough has identified the Epstein-Barr virus (EBV) as the leading cause of multiple sclerosis (MS), ...

Trethera Treats a Late Stage, Heavily Pretreated Amyotrophic Lateral Sclerosis (ALS) Patient with TRE 515 Mar. 31, 2025 9:30 AM ET ...

National Researchers studying whether medical cannabis could help late-stage dementia patients by: Josh Shortt Posted: Jan 26, 2025 / 08:01 AM HST Updated: Jan 26, 2025 / 08:18 AM HST SHARE ...

"The on-schedule enrollment of the final patients in our phase 3 ENSURE trials of vidofludimus calcium marks another significant milestone for our late-stage MS program, bringing us meaningfully ...

Trethera Treats a Late Stage, Heavily Pretreated Amyotrophic Lateral Sclerosis (ALS) Patient with TRE 515 Provided by GlobeNewswire Mar 31, 2025, 1:30:00 PM ...

– Enrollment Completed for Both Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Top-Line Data Expected End of 2026 – – Additional Data from Phase 2 CALLIPER ...